Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.57 USD
+0.11 (0.29%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.57 USD
+0.11 (0.29%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).
Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%
by Zacks Equity Research
Halozyme Therapeutics (HALO) was a big mover last session, as the company saw its shares rise more than 21% on the day amid huge volumes.
Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval
by Zacks Equity Research
Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.
Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season
by Zacks Equity Research
Halozyme Therapeutics (HALO) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) saw its shares rise above 6% in the last trading session.
Can the Rally in Halozyme (HALO) Shares Continue?
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) has been on the move lately as the stock has risen by 15.1% in the past four weeks, and it is currently trading well above its 20-Day SMA.
Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) shares rose almost 18% in the last trading session.
Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
by Zacks Equity Research
Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.